Life-Long Correction of Hyperbilirubinemia with a Neonatal Liver-Specific AAV-Mediated Gene Transfer in a Lethal Mouse Model of Crigler–Najjar Syndrome

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Human Gene Therapy

• Publication date

  2014-07-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/hum.2013.233PMID 25072305PMCID PMC4175423
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia

  2014cited by this paper
• Monogenic diseases that can be cured by liver transplantation.

  2013cited by this paper
• Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer.

  2012cited by this paper
• Recent Progress in Gene Therapy for Hemophilia

  2012cited by this paper
• Sustained Reduction of Hyperbilirubinemia in Gunn Rats After Adeno-Associated Virus-Mediated Gene Transfer of Bilirubin UDP-Glucuronosyltransferase Isozyme 1A1 to Skeletal Muscle

  2012cited by this paper
• Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer

  2012cited by this paper
• Gene therapy for haemophilia: a long and winding road

  2011cited by this paper
• Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

  2011cited by this paper
• Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges

  2011cited by this paper
• Towards liver-directed gene therapy for Crigler-Najjar syndrome.

  2009cited by this paper
• Highly sensitive method for quantitative determination of bilirubin in biological fluids and tissues.

  2008cited by this paper
• Gene delivery to the juvenile mouse liver using AAV2/8 vectors.

  2008cited by this paper
• Disruption of the Ugt1 Locus in Mice Resembles Human Crigler-Najjar Type I Disease*

  2008cited by this paper
• Gene Delivery to the Juvenile Mouse Liver Using AAV2/8 Vectors.

  2008cited by this paper
• Targeting bile-acid signalling for metabolic diseases

  2008cited by this paper
• Tissue- and Gender-Specific mRNA Expression of UDP-Glucuronosyltransferases (UGTs) in Mice

  2007influential reference
• Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.

  2006cited by this paper
• Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione.

  2006cited by this paper
• Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats.

  2006cited by this paper
• Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice

  2005influential reference
• Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models.

  2005influential reference
• Long-term correction of hyperbilirubinemia in the Gunn rat by repeated intravenous delivery of naked plasmid DNA into muscle.

  2005influential reference
• CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice

  2005cited by this paper
• Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart

  2005cited by this paper
• The human multidrug-resistance-associated protein MRP1 mediates ATP-dependent transport of unconjugated bilirubin.

  2004cited by this paper
• Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo.

  2004cited by this paper
• Nonviral Gene Transfer into Liver and Muscle for Treatment of Hyperbilirubinemia in the Gunn Rat

  2004influential reference
• Molecular basis of bilirubin-induced neurotoxicity.

  2004cited by this paper
• Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

  2003influential reference
• Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway.

  2003cited by this paper
• The hepatocyte: heterogeneity and plasticity of liver cells.

  2003cited by this paper
• Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance

  2000cited by this paper
• Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

  2000influential reference
• Structure of Adeno-Associated Virus Vector DNA following Transduction of the Skeletal Muscle

  1999cited by this paper
• Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation.

  1998cited by this paper
• ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2.

  1997cited by this paper
• Epidemiology of coagulation disorders.

  1992influential reference
• Quantitation of transplanted hepatic mass necessary to cure the Gunn rat model of hyperbilirubinemia.

  1992cited by this paper
• Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry.

  1990cited by this paper
• Reverse-phase h.p.l.c. separation, quantification and preparation of bilirubin and its conjugates from native bile. Quantitative analysis of the intact tetrapyrroles based on h.p.l.c. of their ethyl anthranilate azo derivatives.

  1985cited by this paper
• Measurement of protein using bicinchoninic acid.

  1985cited by this paper
• Mechanism and subcellular site of bilirubin diglucuronide formation in rat liver.

  1984influential reference
• DIRECT SPECTROPHOTOMETRIC DETERMINATION OF ALBUMIN IN HUMAN SERUM.

  1965cited by this paper

• Bilirubin Triggers Calcium Elevations and Dysregulates Giant Depolarizing Potentials During Rat Hippocampus Maturation

  2025cites this paper
• Delivery of Thermogenic Genes to Metabolic Tissues: Effects on Body Weight and Glucose Tolerance.

  2025cites this paper
• Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy

  2024cites this paper
• Repeated dosing of AAV-mediated liver gene therapy in juvenile rat and mouse models of Crigler-Najjar syndrome type I

  2024cites this paper
• Current and Emerging Issues in Adeno-Associated Virus Vector-Mediated Liver-Directed Gene Therapy

  2024cites this paper
• Gene Therapy for Inherited Liver Disease: To Add or to Edit

  2024cites this paper
• Developing and evaluating a predictive model for neonatal hyperbilirubinemia based on UGT1A1 gene polymorphism and clinical risk factors

  2024cites this paper
• Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates

  2023cites this paper
• Genetic alterations and molecular mechanisms underlying hereditary intrahepatic cholestasis

  2023cites this paper
• Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa−/− mice

  2023cites this paper
• Successful treatment of severe MSUD in Bckdhb−/− mice with neonatal AAV gene therapy

  2023cites this paper
• Intrathymic AAV delivery results in therapeutic site-specific integration at TCR loci in mice

  2023cites this paper
• Lipid nanoparticle-encapsulated mRNA therapy corrects serum total bilirubin level in Crigler-Najjar syndrome mouse model

  2023cites this paper
• Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates

  2023cites this paper
• CRISPR-Cas9-mediated somatic correction of a one-base deletion in the Ugt1a gene ameliorates hyperbilirubinemia in Crigler-Najjar syndrome mice

  2023cites this paper
• Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents

  2023cites this paper
• Auxiliary Partial Orthotopic Liver Transplantation (APOLT) for Crigler-Najjar Syndrome: A Retrospective Analysis

  2023cites this paper
• Lethality rescue and long-term amelioration of a citrullinemia type I mouse model by neonatal gene-targeting combined to SaCRISPR-Cas9

  2023cites this paper
• Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency

  2023cites this paper
• Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice

  2022cites this paper
• Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice

  2022influential citation
• What’s next in gene therapy for Crigler-Najjar syndrome?

  2022cites this paper
• Rescue of a familial dysautonomia mouse model by AAV9-Exon-specific U1 snRNA.

  2022cites this paper
• Challenges and opportunities when transitioning from in vivo gene replacement to in vivo CRISPR/Cas9 therapies – a spotlight on hemophilia

  2022cites this paper
• Disease burden and management of Crigler‐Najjar syndrome: Report of a world registry

  2022cites this paper
• Low efficacy of recombinant SV40 in Ugt1a1-/- mice with severe inherited hyperbilirubinemia

  2021cites this paper
• Disorders of bilirubin and lipid metabolism

  2021cites this paper
• Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates

  2021cites this paper
• Gene Therapy

  2021cites this paper
• A novel therapeutic strategy for skeletal disorders: Proof of concept of gene therapy for X-linked hypophosphatemia

  2021cites this paper
• Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy

  2021cites this paper
• Diagnostic methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments

  2021cites this paper
• Targeted Gene Delivery: Where to Land

  2021cites this paper
• Adeno-Associated Virus Serotype 8-Mediated Genetic Labeling of Cholangiocytes in the Neonatal Murine Liver

  2020cites this paper
• Disease burden of Crigler–Najjar syndrome: Systematic review and future perspectives

  2020cites this paper
• Crigler‐Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier

  2020cites this paper
• Human liver stem cells express UGT1A1 and improve phenotype of immunocompromised Crigler Najjar syndrome type I mice

  2020cites this paper
• Capsid-specific removal of circulating antibodies to adeno-associated virus vectors

  2020cites this paper
• Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease

  2020cites this paper
• Liver‐Directed Gene Therapy

  2020cites this paper
• Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase

  2020cites this paper
• A Quantitative In Vitro Potency Assay for Adeno-Associated Virus Vectors Encoding for the UGT1A1 Transgene

  2020cites this paper
• Pompe disease: pathogenesis, molecular genetics and diagnosis

  2020cites this paper
• Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector

  2020cites this paper
• Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4−/− mouse model of PFIC3

  2020cites this paper
• Efficacy of AAV8-hUGT1A1 with Rapamycin in neonatal, suckling, and juvenile rats to model treatment in pediatric CNs patients

  2020cites this paper
• In vitro and in vivo translational models for rare liver diseases.

  2019cites this paper
• Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler–Najjar Syndrome

  2019cites this paper
• Liver-directed gene therapy results in long-term correction of progressive familial intrahepatic cholestasis type 3 in mice.

  2019cites this paper
• Experimental models assessing bilirubin neurotoxicity

  2019cites this paper
• Progress and challenges of gene therapy for Pompe disease.

  2019cites this paper
• Genetic-Based Approaches to Inherited Metabolic Liver Diseases

  2019cites this paper
• Gene Therapy for Pompe Disease: The Time is now

  2019cites this paper
• Growth Differentiation Factor 11 and Myostatin: Mechanism and Therapeutic Role in Cardiovascular Diseases

  2019cites this paper
• Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA

  2019cites this paper
• Gene Therapy in Pediatric Liver Disease

  2019cites this paper
• AAV8 Gene Therapy Rescues the Newborn Phenotype of a Mouse Model of Crigler–Najjar

  2018cites this paper
• Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases.

  2018influential citation
• DNA damage induction by bilirubin induced oxidative stress and activation of DNA repair pathways by bilirubin

  2018cites this paper
• Advances in understanding disease mechanisms and potential treatments for Crigler–Najjar syndrome

  2018cites this paper
• Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome

  2018cites this paper
• Bilirubin-Induced Oxidative Stress Leads to DNA Damage in the Cerebellum of Hyperbilirubinemic Neonatal Mice and Activates DNA Double-Strand Break Repair Pathways in Human Cells

  2018cites this paper
• AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice

  2018cites this paper
• Exposure to wild-type AAV drives distinct capsid immunity profiles in humans

  2018cites this paper
• Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

  2018cites this paper
• Determining the Minimally Effective Dose of a Clinical Candidate AAV Vector in a Mouse Model of Crigler-Najjar Syndrome

  2018cites this paper
• Emerging Issues in AAV-Mediated In Vivo Gene Therapy

  2017cites this paper
• Promoterless gene targeting without nucleases rescues lethality of a Crigler‐Najjar syndrome mouse model

  2017influential citation
• Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler–Najjar Syndrome Type I

  2017cites this paper
• Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase

  2017cites this paper
• Liver induced transgene tolerance with AAV vectors.

  2017cites this paper
• Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial

  2017cites this paper
• Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity

  2017cites this paper
• In vivo evaluation of biomolecular mechanisms of bilirubin toxicity and pre-clinical therapies.

  2017cites this paper
• AAV Vector-Based Gene Therapy, Progress and Current Challenges

  2017cites this paper
• Targeted delivery of AAV‐transduced mesenchymal stromal cells to hepatic tissue for ex vivo gene therapy

  2017cites this paper
• A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome

  2016cites this paper
• Hepatocyte-specific drug delivery using active targeted nanomedicines - evaluation of targeting strategies in vitro and in vivo

  2016cites this paper
• Composition pour le traitement du syndrome de crigler-najjar

  2016cites this paper
• Progress and challenges in gene therapy for Crigler–Najjar syndrome

  2015cites this paper
• Impairment of enzymatic antioxidant defenses is associated with bilirubin-induced neuronal cell death in the cerebellum of Ugt1 KO mice

  2015cites this paper
• Albumin administration prevents neurological damage and death in a mouse model of severe neonatal hyperbilirubinemia

  2015cites this paper
• Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseases.

  2015cites this paper
• Gene Therapy for Inherited Diseases of Liver Metabolism

  2015cites this paper